Immuron taking forward new therapy for fatty liver disease
This article was originally published in Scrip
Executive Summary
The Australian firm Immuron is planning to submit by the end of this year a US IND to begin a multinational Phase IIb trial with a potential treatment for non-alcoholic steatohepatitis (NASH), with the aim of starting enrolment in the first half of 2012.